Want to see IN:SUVEN full AI Analyst Report?
Total Valuation
Suven Life Sciences Limited has a market cap or net worth of ₹86.38B. The enterprise value is ₹55.65B.
Market Cap₹86.38B
Enterprise Value₹55.65B
Share Statistics
Suven Life Sciences Limited has 263,720,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding263,720,580
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Suven Life Sciences Limited’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -47.56%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-47.56%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee504.59K
Profits Per Employee-19.60M
Employee Count141
Asset Turnover0.01
Inventory Turnover480.81
Valuation Ratios
The current PE Ratio of Suven Life Sciences Limited is ―. Suven Life Sciences Limited’s PEG ratio is -0.17.
PE Ratio―
PS Ratio421.72
PB Ratio5.07
Price to Fair Value5.07
Price to FCF-9.91
Price to Operating Cash Flow-65.05
PEG Ratio-0.17
Income Statement
In the last 12 months, Suven Life Sciences Limited had revenue of 71.15M and earned -2.76B in profits. Earnings per share was -12.13.
Revenue71.15M
Gross Profit-419.28M
Operating Income-2.90B
Pretax Income-2.76B
Net Income-2.76B
EBITDA-2.85B
Earnings Per Share (EPS)-12.13
Cash Flow
In the last 12 months, operating cash flow was -1.03B and capital expenditures -21.37M, giving a free cash flow of -1.06B billion.
Operating Cash Flow-1.03B
Free Cash Flow-1.06B
Free Cash Flow per Share-4.00
Dividends & Yields
Suven Life Sciences Limited pays an annual dividend of ₹1.382, resulting in a dividend yield of ―
Dividend Per Share₹1.382
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.87
52-Week Price Change28.58%
50-Day Moving Average249.97
200-Day Moving Average192.10
Relative Strength Index (RSI)73.78
Average Volume (3m)14.83K
Important Dates
Suven Life Sciences Limited upcoming earnings date is Aug 10, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Suven Life Sciences Limited as a current ratio of 17.69, with Debt / Equity ratio of 2.82%
Current Ratio17.69
Quick Ratio17.69
Debt to Market Cap0.00
Net Debt to EBITDA1.13
Interest Coverage Ratio-1.84K
Taxes
In the past 12 months, Suven Life Sciences Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Suven Life Sciences Limited EV to EBITDA ratio is -9.42, with an EV/FCF ratio of -8.85.
EV to Sales376.63
EV to EBITDA-9.42
EV to Free Cash Flow-8.85
EV to Operating Cash Flow-9.01
Balance Sheet
Suven Life Sciences Limited has ₹5.18B in cash and marketable securities with ₹166.94M in debt, giving a net cash position of ₹5.01B billion.
Cash & Marketable Securities₹5.18B
Total Debt₹166.94M
Net Cash₹5.01B
Net Cash Per Share₹19.01
Tangible Book Value Per Share₹25.95
Margins
Gross margin is -413.70%, with operating margin of -4077.70%, and net profit margin of -3884.13%.
Gross Margin-413.70%
Operating Margin-4077.70%
Pretax Margin-3884.13%
Net Profit Margin-3884.13%
EBITDA Margin-3998.80%
EBIT Margin-4077.70%
Analyst Forecast
The average price target for Suven Life Sciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.89%
EPS Growth Forecast-67.45%